Teva again raises guidance as branded drugs lift revenue

Revenue in the third quarter was $4.4 billion, while analysts had predicted $4.2 billion and non-GAAP earnings per share was $0.86, well above the analysts’ consensus of $0.72.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (en.globes.co.il)